前列腺癌立体定向MRI引导自适应放疗(SMART)的长期结局:真实世界大样本队列结果
本研究基于单中心前瞻性数据库,纳入2016至2021年接受SMART的464例局限期前列腺癌患者,5次7.25 Gy分割,中位随访48.8个月。结果显示急性和晚期≥2级毒性低,但高危组5年生化或临床失败无进展生存率低于低中危组,改进分期可优化风险分层。
要点
- SMART方案为5次7.25 Gy,中位随访48.8个月,≥2级晚期胃肠和泌尿毒性分别为0.2%和6.5%。
- 高危组5年无生化或临床失败生存率为74.9%,低于低危100%和中危77.7%。
- 纳入诊断影像改进分期后,高危组对应生存率调整为71.6%,提示可指导高危患者剂量提升。
核心结论
- SMART治疗局限期前列腺癌急性和晚期毒性低,但高危患者生化及临床控制率低于低中危患者。
- 改进分期可细化风险分类,指导高危患者治疗强化如剂量提升。
研究设计与样本
- 单中心前瞻性数据库纳入2016至2021年连续464例局限期前列腺癌患者,涵盖所有风险类别。
- 治疗为5次7.25 Gy立体定向MRI引导自适应放疗,尽量在2周内完成,常规评估急性和晚期毒性及生化复发。
主要发现
- 中位年龄72岁(范围50-89),中危占50.0%,高危占44.8%(基于EAU指南)。
- 急性≥2级胃肠和泌尿毒性发生率分别为5.2%和19.8%,累积晚期≥2级胃肠和泌尿毒性分别为0.2%和6.5%。
- 中位随访48.8个月(IQR 36.3-63.5),76例(16.4%)复发,多数在高危组。
- 低、中、高危组估计5年无生化或临床失败生存率分别为100%(95%CI 100-100)、77.7%(95%CI 68.2-84.7)和74.9%(95%CI 66.2-81.7)。
- 纳入诊断影像分期后,对应生存率分别为100%(95%CI 100-100)、85.5%(95%CI 76.6-91.2)和71.6%(95%CI 63.2-78.4)。
关键数值与推荐
- 生化复发采用Phoenix标准(前列腺特异性抗原最低点+2)定义,局部、区域或远处复发经PSMA PET-CT确认。
- 风险分组基于EAU指南。
临床怎么用
- SMART可作为局限期前列腺癌的低毒性治疗选择,尤其适用于低中危患者。
- 高危患者SMART后控制率较低,应考虑治疗强化如剂量提升,并利用改进分期优化风险分层。
局限性
- 单中心真实世界研究,非随机对照,可能存在选择偏倚。
- 随访时间有限,长期结局需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic magnetic resonance imaging-guided adaptive radiation therapy (SMART) has emerged as a treatment for localized prostate cancer with excellent acute toxicity outcomes. However, long-term outcomes have not been reported. This study reports on long-term outcomes of SMART for prostate cancer in a single institution. METHODS AND MATERIALS: We included consecutive patients with localized prostate cancer treated with SMART in an institutional prospective database comprising all risk categories. Treatment was delivered in 5 fractions of 7.25 Gy with daily online adaptation, preferably within 2 weeks. Acute and late toxicity as well as biochemical recurrences were routinely assessed during follow-up. Biochemical recurrence was defined by Phoenix criteria (prostate-specific antigen nadir + 2), and local, regional, or distant recurrence was confirmed by PSMA PET-CT imaging. RESULTS: From 2016-2021, 464 patients were analyzed. Median age was 72 years (range, 50-89) and the majority of patients had intermediate (50.0%) or high (44.8%) risk prostate cancer based on EAU guidelines. Acute gastrointestinal and genitourinary toxicity grade ≥2 rates were 5.2% and 19.8%, and cumulative late gastrointestinal and genitourinary toxicity grade ≥2 rates were 0.2% and 6.5%, respectively. After a median follow-up of 48.8 months (IQR, 36.3-63.5), 76 recurrences (16.4%) were recorded, most occurred in the high-risk group. Estimated 5-year freedom from biochemical or clinical failure for low-, intermediate-, and high-risk subgroups was 100% (95% CI, 100-100), 77.7% (95% CI, 68.2-84.7) and 74.9% (95% CI, 66.2-81.7), respectively. Incorporation of diagnostic imaging in tumor staging improved risk stratification and led to corresponding rates of 100% (95% CI, 100-100), 85.5% (95% CI, 76.6-91.2), and 71.6% (95% CI, 63.2-78.4). CONCLUSIONS: In this large cohort of patients with prostate cancer treated with SMART, acute and late toxicity was low. Biochemical and clinical control for high-risk patients was lower than for low- and intermediate-risk patients. Improved staging refines risk classification, guiding treatment intensification such as dose escalation in high-risk patients.
引用
- van Vliet C, Tetar SU, Bohoudi O, et al. Long-Term Outcomes of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Prostate Cancer: Results From a Real-World Large Patient Cohort. Int J Radiat Oncol Biol Phys. 2026. PMID: 41544676. doi:10.1016/j.ijrobp.2025.12.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。